Survodutide Shows Promise for MASLD and Obesity in Clinical Trial Results

Survodutide, a glucagon/GLP-1 receptor dual agonist, demonstrated significant efficacy in reducing liver fat and body weight in a 48-week, placebo-controlled trial for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity. According to the study, 84.2% of participants receiving 6.0 mg of survodutide weekly achieved a reduction in liver fat content (LFC) of 30% or greater, compared to 24.3% in the placebo group.

How Survodutide Affects Liver Fat and Inflammation

The trial, which concluded in December 2025, evaluated the drug’s impact on liver health using magnetic resonance imaging (MRI-PDFF). Beyond the primary endpoint of LFC reduction, researchers observed substantial improvements in secondary markers of liver health. Participants treated with survodutide experienced a mean relative change in LFC of -58.7%, compared to -9.5% for those on a placebo. Furthermore, 63.0% of the treatment group achieved an absolute reduction in iron-corrected T1 (cT1) levels of at least 80 ms, a threshold linked to histological improvement in liver inflammation.

Liver stiffness, a key indicator of fibrosis, also showed improvement in the treatment arm. Patients receiving survodutide saw a 28.7% reduction in stiffness as measured by vibration-controlled transient elastography (VCTE), compared to a 9.2% reduction in the placebo group. Additionally, the enhanced liver fibrosis (ELF) score decreased by 0.34 in the treatment group, providing further evidence of the drug’s potential in managing fibroinflammatory activity in the liver.

Impact on Body Weight and Metabolic Health

Weight loss was a co-primary endpoint of the study, reflecting the strong link between obesity and metabolic liver disease. At 48 weeks, participants receiving survodutide achieved a mean body weight reduction of 12.2%, compared to 1.0% in the placebo group. Nearly 80% of those in the treatment arm lost at least 5% of their initial body weight.

The metabolic benefits extended to other cardiovascular and metabolic risk factors as well. Patients treated with survodutide showed significant reductions in waist circumference, with a mean decrease of 11.1 cm. Researchers also noted improvements in systolic and diastolic blood pressure, as well as favorable changes in HbA1c, triglycerides, and cholesterol levels, suggesting a systemic benefit beyond liver-specific outcomes.

Safety Profile and Treatment Considerations

The clinical trial reported that 87.0% of participants in the survodutide group experienced at least one adverse event, compared to 78.6% in the placebo group. These events were primarily gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Most of these side effects occurred during the dose-escalation phase of the study and were characterized as mild to moderate in intensity.

Treatment discontinuation due to adverse events occurred in 19.9% of the survodutide group and 4.3% of the placebo group. Importantly, the study found no instances of adjudicated drug-induced liver injury, acute pancreatitis, or thyroid cancer among those receiving the treatment. Heart rate monitoring indicated a modest mean increase of 3.6 beats per minute in the survodutide arm by week 52, with no clinically significant changes in QTcF intervals observed.

Trial Overview

• Study Period: April 2, 2024, to December 2, 2025.
• Participants: 216 adults with obesity and at-risk MASLD.
• Dosing: Once-weekly subcutaneous injection, with a 24-week dose-escalation period followed by a 24-week maintenance period.
• Core Findings: Significant improvements in MRI-assessed liver fat, body weight, liver inflammation markers, and metabolic health parameters.